CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO)
DOI 10.1055/a-2723-3284
Bibliografische Angaben
Nachweis in CareLit
Autor:innenSyed Qaiser Shah, Ralph Santos-Oliveira, DeryaIlem Ozdemir, Saba Shirin
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe06/2025
Jahrgang / SeitenJg. 64 · S. 332-340
Kernaussage aus der Literatur
Abstract-Vorschau
Abstract Aim To develop a site-specifically radiolabeled version of IMMU-132 (sacituzumab govitecan) using zirconium-89 (⁸⁹Zr) with the chelator 3,4,3-LI(1,2-HOPO) and evaluate its stability, specificity, and quantitative targeting ability in TROP-2–positive prostate cancer models. Methods IMMU-132 was conjugated to 3,4,3-LI(1,2-HOPO)-maleimide and its integrity was confirmed by SDS-PAGE, SE-HPLC and mass spectromet…
Zitieren
Zitierempfehlung
Syed Qaiser Shah, Ralph Santos-Oliveira, DeryaIlem Ozdemir, Saba Shirin (2025) Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO). Nuklearmedizin - NuclearMedicine, 64 (06), 332-340. https://doi.org/10.1055/a-2723-3284
Mit CareLit weiterarbeiten